SS
TCON

Steve Schonfeld’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

Steve Schonfeld’s Portfolio TCON Stock Details TCON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,100
Closed -$492K – 2194
2020
Q4 		$492K Buy
+2,100
New +$292K 0.01% 1043

Other funds holding TCON

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Steve Schonfeld's TCON Position: Q1 2021 in Review

Steve Schonfeld sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q1 2021, closing a stake of 2,100 shares — an estimated $492K sold.

Steve Schonfeld first reported a position in TCON in Q4 2020 and held it in 1 quarter. The position peaked at $492K in Q4 2020. 42 funds tracked by Wall St. Rank hold TCON as of Q1 2021.

  • Steve Schonfeld reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Steve Schonfeld sold 2,100 TRACON Pharmaceuticals, Inc. Common Stock shares in Q1 2021, an estimated $492K.
  • Steve Schonfeld first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Steve Schonfeld's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $492K in Q4 2020.
  • 42 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q1 2021.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2021, filed 17 May 2021.